Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: The present disclosure relates to methods of preparing personalized blood vessels, useful for transplantation with improved host compatibility and reduced susceptibility to thrombosis. Also provided are personalized blood vessels produced by the methods and use thereof in surgery.

Abstract: An in vitro toxicity assay based on human blastocyst-derived stem cells for the detection of toxicity in the human species is provided, which enables novel detection of in vitro human toxicity for a substance and/or more efficiently detects human toxicity compared to non-human assays. Furthermore, the detection of toxicity for substances is enabled, which is known to display inter-species differences and the toxic effect was not detectable by toxicological tests in mice.

Abstract: The present invention discloses a novel antibody HES5:3:3 directed towards a specific antigen present on human pluripotent stem (hPS) cells and cancer tissue. The antibody can be used as a tool for human pluripotent stem (hPS) cell applications, such as the separation, surface adhesion and enhanced survival of said hPS cells. Furthermore, the present invention refers to the use of the antigen detection for cancer applications.

Abstract: A combined scalable in vitro differentiation and assay system based on human blastocyst-derived stem (hBS) cells or cells derived from hBS cells is provided. This system makes it possible to merge both the differentiation and the assay parts of the system into one. The advantage of the combined assay system is that the hBS cells or the cells derived from hBS cells in the differentiation system are directly applicable for assays, in a large variety of assay units, such as different multiwell plates. The system offers a major improvement compared to the prior art, since the cells are differentiated in the same format as when further being subject to analysis. The starting cell material can be homogenously distributed across a variety of different plates, for use and can be cultured when attached, when semi-attached or when in suspension.

Abstract: Described herein is a mesenchymal human progenitor (hBS-MP) cell population derived from human blastocyst-derived stem (hBS) cells and a method to obtain the progenitor cell population in which is eliminated the need of co-culture steps, cell sorting, manual selection, and transfections. Also, the use of the hBS-MP cells in drug discovery and specifically for toxicity testings as well as for therapeutic use is made possible.

Abstract: A method for obtaining a stable xeno-free hBS cell line, xeno-free hBS cell lines obtained according to said method and use thereof.

Abstract: An in vitro toxicity assay based on human blastocyst-derived stem cells for the detection of toxicity in the human species is provided, which enables novel detection of in vitro human toxicity for a substance and/or more efficiently detects human toxicity compared to non-human assays. Furthermore, the detection of toxicity for substances is enabled, which is known to display inter-species differences and the toxic effect was not detectable by toxicological tests in mice.

Abstract: The present invention relates to a culture system for and a method for propagation of human blastocyst-derived stem cells (hBS cells) upon enzymatic dissociation into a single cell suspension. The culture system for propagation of human blastocyst-derived stem (hBS) cells comprises i) human feeder cells at a density of at least 50,000 cells/cm2, ii) one or more dissociation agents for dissociation of hBS cell colonies into a single cell suspension, and iii) a supportive culture medium, which culture system makes it possible to propagate hBS cells by dissociation of hBS cell colonies into a single cell suspension at each consecutive passage for an extended time period, while maintaining the significant characteristics of hBS cells.

Abstract: The invention relates to an in vitro toxicity assay based on human blastocyst-derived stem cells for the detection of toxicity in the human species, which enables novel detection of in vitro human toxicity for a substance and/or more efficiently detects human toxicity compared to non-human assays. The invention can furthermore enable detection of toxicity for substances, which are known to display inter-species differences and the toxic effect was not detectable by toxicological tests in mice.